Hyperferritinemia in patients with nonalcoholic fatty liver disease

Revista da Associacao Medica Brasileira

Volumn 63, Issue 3, 2017, Pages 284-289

  Barros, Raffaelle K ^a   Cotrim, Helma Pinchemel ^a   Daltro, Carla H ^a   Oliveira, Yanaihara A ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

Author keywords

Hyperferritinemia.; Nonalcoholic Fatty Liver Disease; Steatohepatitis; Steatosis

Indexed keywords

FERRITIN; IRON;

DIAGNOSTIC ACCURACY; DISEASE ASSOCIATION; FERRITIN BLOOD LEVEL; HEMOCHROMATOSIS; HUMAN; HYPERFERRITINEMIA; INSULIN RESISTANCE; LIVER BIOPSY; LIVER CELL DAMAGE; LIVER FIBROSIS; NONALCOHOLIC FATTY LIVER; PREDICTIVE VALUE; REVIEW; SENSITIVITY AND SPECIFICITY; BLOOD; COMPLICATION; IRON OVERLOAD; PATHOLOGY; RISK FACTOR;

FERRITINS; HUMANS; IRON; IRON OVERLOAD; NON-ALCOHOLIC FATTY LIVER DISEASE; RISK FACTORS;

EID: 85019669172     PISSN: 01044230     EISSN: None     Source Type: Journal    
DOI: 10.1590/1806-9282.63.03.284     Document Type: Review

References (31)

1. Angulo P, George J, Day CP, Vanni E, Russell L, De la Cruz AC, et al. Serum ferritin levels lack diagnostic accuracy for liver fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2014; 12(7):1163-9.
2. Valenti L, Dongiovanni P, Fargion S. Diagnostic and therapeutic implications of the association between ferritin level and severity of nonalcoholic fatty liver disease. World J Gastroenterol. 2012; 18(29):3782-6.
3. Chandok N, Minuk G, Wengiel M, Uhanova J. Serum ferritin levels do not predict the stage of underlying non-Alcoholic fatty liver disease. J Gastrointestin Liver Dis. 2012; 21(1):53-8.
4. Ferrannini E. Insulin resistence, iron, and the liver. Lancet. 2000; 355(9222):2181-2.
5. Ferreira VSG, Pernambuco RB, Lopes EP, Morais CN, Rodrigues MC, Arruda MJ, et al. Frequency and risk factors associated with nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Arq Bras Endocrinol Metabol. 2010; 54(4):362-8.
6. Adams LA, Crawford DH, Stuart K, House MJ, St Pierre TG, Webb M, et al. The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology. 2015; 61(5):1555-64.
7. Cipp PE, Boucsein I, Adams H, Krayenbuehl PA. Estimating iron overload in patients with suspected liver disease and elevated serum ferritin. Am J Med. 2014; 127(10):1011.e1-3.
8. Kowdley KV, Belt P, Wilson LA, Yeh MM, Neuschwander-Tetri BA, Chalasani N, et al.; NASH Clinical Research Network. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012; 55(1):77-85.
9. Cotrim HP. Hyperferritinaemia. UEG Week 2013; 148-51. Available from: https://d1m2qru0mx8rl9.cloudfront.net/uegfolga-web/uegf-ep-mat089/IP060.pdf.
10. Kell DB, Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014; 6(4):748-73.
11. Manousou P, Kalambokis G, Grillo F, Watkins J, Xirouchakis E, Pleguezuelo M, et al. Serum ferritin is a discriminant marker for both fibrosis and inflammation in histologically proven non-Alcoholic fatty liver disease patients. Liver Int. 2011; 31(5):730-9.
12. Yoneda M, Nozaki Y, Endo H, Mawatari H, Iida H, Fujita K, et al. Serum ferritin is a clinical biomarker in Japanese patients with nonalcoholic steatohepatitis (NASH) independent of HFE gene mutation. Dig Dis Sci. 2010; 55(3):808-14.
13. Brunt EM, Kleiner DE, Wilson LA, Belt P, Neuschwander-Tetri BA; NASH Clinical Research Network (CRN). Nonalcoholic fatty liver disease (NAFLD) activity score and the histopathologic diagnosis in NAFLD: distinct clinicopathologic meanings. Hepatology. 2011; 53(3):810-20.
14. Aigner E, Weiss G, Datz C. Dysregulation of copper homeostasis in nonalcoholic fatty liver. World J Hepatol. 2015; 7(2):177-88.
15. Adams P, Barton J. A diagnostic approach to hyperferritinemia with a nonelevated transferrin saturation. J Hepatol. 2011; 55(2):453-8.
16. Zimmermann A, Zimmermann T, Schattenberg J, Ptgen S, Lotz J, Rossmann H, et al. Alterations in lipid, carbohydrate and iron metabolism in patients with non-Alcoholic steatohepatitis (NASH) and metabolic syndrome. Eur J Intern Med. 2011; 22(3):305-10.
17. Brudevold R, Hole T, Hammerstr J. Hyperferritinemia is associated with insulin resistance and fatty liver in patients without iron overload. PLoS ONE. 2008; 3(10):e3547.
18. Williamson RM, Price JF, Glancy S, Perry, E, Nee LD, Hayes PC, et al.; Edinburgh Type 2 Diabetes Study Investigators. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: The Edinburgh type 2 diabetes study. Diabetes Care. 2011; 34(5):1139-44.
19. Nakajima T, Nakashima T, Yamaoka J, Shibuya A, Itoh Y, Yoshikawa T. Age is a negative, and visceral fat accumulation is a contributor to hepatic steatosis, regardless of the progression in non-Alcoholic fatty liver disease. J Gastroenterol Hepatol Res. 2012; 1(11):315-9.
20. Bozzini C, Girelli D, Olivieri O, Martinelli N, Bassi A, De Matteis G, et al. Prevalence of body iron excess in the metabolic syndrome. Diabetes Care. 2005; 28(8):2061-3.
21. Bell H, Skinningsrud A, Raknerud N, Try N. Serum ferritin and transferrin saturation in patients with chronic alcoholic and non-Alcoholic liver diseases. J Intern Med. 1994; 236(3):315-22.
22. Tung BY, Emond MJ, Bronner MP, Raaka SD, Cotler SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology. 2003; 124(2):318-26.
23. Ucar F, Sezer S, Erdogan S, Akyol S, Armutcu F, Akyol O. The relationship between oxidative stress and nonalcoholic fatty liver disease: its effects on the development of nonalcoholic steatohepatits. Redox Rep. 2013; 18(4):127-33.
24. Wieckowska A, Papouchado BG, Li Z, Lopez R, Zein NN, Feldstein AE. Increased hepatic and circulating interleukin-6 levels in human nonalcoholic steatohepatitis. Am J Gastroenterol. 2008; 103(6):1372-9.
25. Estep JM, Baranova A, Hossain N, Elariny H, Ankrah K, Afendy A, et al. Expression of cytokine signaling genes in morbidly obese patients with nonalcoholic steatohepatitis and hepatic fibrosis. Obes Surg. 2009; 19(5):617-24.
26. Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in nonalcoholic steatohepatitis. Clin Liver Dis. 2009; 13(4):565-80.
27. Ibrahim MA, Kelleni M, Geddawy A. Nonalcoholic fatty liver disease: current and potential therapies. Life Sci. 2013; 92(2):114-8.
28. Wang Y, Zhou M, Lam KS, Xu A. Protective roles of adiponectin in obesityrelated fatty liver diseases: mechanisms and therapeutic implications. Arq Bras Endocrinol Metab. 2009; 53(2):201-12.
29. Valenti L, Fracanzani AL, Dongiovanni P, Rovida S, Rametta R, Fatta E, et al. A randomized trial of iron depletion in patients with nonalcoholic fatty liver disease and hyperferritinemia. World J Gastroenterol. 2014; 20(11):3002-10.
30. Ferndez-Real JM, McClain D, Manco M. Mechanisms linking glucose homeostasis and iron metabolism toward the onset and progression of type 2 diabetes. Diabetes Care. 2015; 38(11):2169-76.
31. Fujita N, Miyachi H, Tanaka H, Takeo M, Nakagawa N, Kobayashi Y, et al. Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis. Cancer Epidemiol Biomark Prev. 2009; 18(2):424-32.